The Business of Biotech was back in San Francisco for JPM in January, and offers here a few observations, highlights, and ...

If someone told you that they were “probably” going to have pasta for dinner, but you later found out that they ate pizza, would you feel surprised – or even lied to? More seriously, what does it mean ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Dr. James McCaffrey presents a complete end-to-end demonstration of decision tree regression from scratch using the C# language. The goal of decision tree regression is to predict a single numeric ...

Investors are split on whether the Federal Reserve will cut interest rates again at its next meeting in less than a month, amid uncertainty following the loss of economic data during the government ...

In the world of government contracting, your pipeline isn’t just a list of leads. It’s the heartbeat of your business. But managing that pipeline without a clear, consistent way to assess each ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

The Hechinger Report covers one topic: education. Sign up for our newsletters to have stories delivered to your inbox. Consider becoming a member to support our nonprofit journalism. Of course, no one ...

Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7) SALT LAKE CITY, Aug. 05, 2025 ...